Thiazole derivatives

Details Thiazole derivatives Thiazole derivatives

2003-08-28

2004-10-26

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S204000

Reexamination Certificate

active

06809110

ABSTRACT:

BACKGROUND OF THE INVENTION
Peroxisome Proliferator Activated Receptors (PPAR's) are members of the nuclear hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes thereof have been identified and cloned. These include PPAR&agr;, PPAR&bgr; (also known as PPAR&dgr;), and PPAR&ggr;. There exist at least two major isoforms of PPAR&ggr;. While PPAR&ggr;1 is ubiquitously expressed in most tissues, the longer isoform PPAR&ggr;2 is almost exclusively found in adipocytes. In contrast, PPAR&agr; is predominantly expressed in the liver, kidney and heart. PPAR's modulate a variety of body responses including glucose- and lipid-homeostasis, cell differentiation, inflammatory responses and cardiovascular events.
Diabetes is a disease in which a patient's ability to control glucose levels in blood is impaired, because he has partially lost the ability to respond properly to the action of insulin. In type II diabetes (T2D), often referred to as non-insulin dependent diabetes mellitus (NIDDM), which afflicts 80-90% of all diabetic patients in developed countries, the Isles of Langerhans in the pancreas still produce insulin. However, the target organs, mainly muscle, liver and adipose tissue, exhibit a profound resistance to insulin stimulation, and the body compensates by producing unphysiologically high levels of insulin. In later stage of disease, however, insulin secretion decreases due to exhaustion of the pancreas. In addition to that T2D is a metabolic-cardiovascular disease syndrome. Among the comorbidities associated with T2D are for example insulin resistance, dyslipidemia, hypertension, endothelial dysfunction and inflammatory atherosclerosis.
Current first line treatment for diabetes generally involves low fat—and glucose—diet and exercise. However, compliance can be moderate and as the disease progresses, treatment with hypoglycemic drugs, e.g. sulfonylureas or metformin, becomes necessary. A promising new class of drugs has recently been introduced that resensitizes patients to their own insulin (insulin sensitizers), thereby reverting blood glucose and triglyceride levels to normal, and thus abolishing, or at least reducing, the requirement for exogenous insulin. Pioglitazone (Actos™) and rosiglitazone (Avandia™) belong to the thiazolidinediones (TZD) class of PPAR&ggr;-agonists and were the first representatives that had been approved for NIDDM in several countries. These compounds, however, suffer from side effects including rare but severe liver toxicity (as seen with troglitazone), and they increase body weight in humans. Therefore, new, better and more efficacious drugs for the treatment of NIDDM are urgently needed. Recent studies provide evidence that a coagonism on PPAR&agr; and PPAR&ggr; would result in compounds with enhanced therapeutic potential, i. e. such compounds should improve the lipid profile in addition to the normalization of glucose- and insulin-levels (Keller and Wahli: Trends Endocrin. Metab. 1993; 4:291-296, Macdonald and Lane: Current Biology Vol.5 pp.618-621 (1995)). Recent observations suggest furthermore that there is an independent PPAR&agr; mediated effect on insulin-sensitzation that could result secondary to the reduction in lipids (Guerre-Millo et al; J Biol Chem2000; 275: 16638-16642). Consequently, the incorporation of PPAR&agr; activity into PPAR&ggr; agonists is expected to give rise to more efficacious drugs for the treatment and/or prevention of diabetes.
SUMMARY OF THE INVENTION
The present invention provides compounds of the formula (I)
wherein
X is N and Y is S; or
X is S and Y is N;
R
1
is aryl or heteroaryl;
R
2
is hydrogen, lower-alkyl or fluoro-lower-alkyl;
R
3
, R
4
, R
5
and R
6
independently from each other are selected from hydrogen, hydroxy, lower-alkenyl, halogen, lower-alkyl, fluoro-lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy, hydroxy-lower-alkoxy, and lower-alkoxy-lower-alkoxy, wherein at least one of R
3
, R
4
, R
5
and R
6
is not hydrogen, or
R
3
and R
4
are bonded to each other to form a ring together with the carbon atoms to which they are attached, and R
3
and R
4
together are —CH═CH—S—, —S—CH═CH—, —CH—CH—O—, —O—CH═CH—, —CH—SH—CH═CH—, —(CH
2
)
3-5
—, —O—(CH
2
)
2-3
— or —(CH
2
)
2-3
—O—, and R
5
and R
6
are as defined above;
R
7
is lower-alkyl, lower-alkoxy, lower-alkenyloxy, aryloxy or aryl-lower-alkoxy,
R
8
is hydrogen or lower-alkyl;
R
9
and R
10
independently from each other are hydrogen, lower-alkyl, lower-alkenyl, cycloalkyl, phenyl or [1,3]dioxan-2-ethyl;
n is 1, 2 or 3;
and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof.


REFERENCES:
patent: 4011326 (1977-03-01), Jensen
patent: 5089514 (1992-02-01), Hulin
patent: 5599826 (1997-02-01), Mertens et al.
patent: 5856529 (1999-01-01), Catt et al.
patent: 6048883 (2000-04-01), Haigh et al.
patent: 6121397 (2000-09-01), MacLeod et al.
patent: 6291685 (2001-09-01), Junghans et al.
patent: 6441185 (2002-08-01), Kühnle et al.
patent: 6498174 (2002-12-01), Collins et al.
patent: 6710063 (2004-03-01), Chao et al.
patent: 0903343 (1999-03-01), None
patent: 1 078 923 (2001-02-01), None
patent: WO 91/19702 (1991-12-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 94/13650 (1994-06-01), None
patent: WO 95/17394 (1995-06-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/10339 (1999-03-01), None
patent: WO 00 08002 (2000-02-01), None
patent: WO 02 16331 (2002-02-01), None
Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296.
MacDougald and Lane: Current Biology vol. 5 pp. 618-621 (1995).
Guerre-Millo, et al.; J Biol Chem2000; 275: 16638-16642.
Balfour, et al.; Drugs 57 (1999) 921-930.
Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367.
Gotteland et al., Synlëtt, 9 pp. 931-932 (1995).
Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996).
Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000).
Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998).
Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000).
Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971).
Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933).
Diels et al., chem.. Ber., 48, pp. 897-905 (1915).
Wightman et al., J. Org. chem.., 43, pp. 2167-2170 (1978).
Musser et al., J. Med. Chem. 30, pp. 62-67 (1987).
Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-2977 (1983).
Kelly et al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988).
Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986).
Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982).
Párkányi et al., Monatsh. Chem., 123, pp. 637-645 (1992).
STN International ® CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract.
Malamas, MS et al, Eur. J. Med. Chem. vol. 36, No. 1 (2001) pp. 31-42.
Hulin, B. et al., Current Pharmaceutical Design, vol. 2 (1990) pp. 85-102.
Oplinger, et. al., ACS National Meeting, San Diego, Apr. 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C.

Affiliated with

Also associated with

Rating

Thiazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3280423